Reappraising the use of β-lactams to treat tuberculosis

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 9, 2012, Pages 999-1006

  Kurz, Sebastian G ^a   Bonomo, Robert A ^b,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

lactam; lactamase; ampicillin clavulanate; clavulanic acid; l,d transpeptidases; Mycobacterium tuberculosis; penicillin binding protein

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CARBENICILLIN; CEFALORIDINE; CEFALOTIN; CEFAZOLIN; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFTRIAXONE; CEFUROXIME; CLAVULANIC ACID; ERTAPENEM; GAMMA GLUTAMYLTRANSFERASE; IMIPENEM; ISONIAZID; MEROPENEM; NAFCILLIN; PENICILLIN BINDING PROTEIN; SULBACTAM; TAZOBACTAM;

ADJUVANT THERAPY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CELL WALL; BIOCHEMISTRY; CELL MEMBRANE PERMEABILITY; DRUG HALF LIFE; DRUG MECHANISM; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; CELL WALL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84868130891     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.96     Document Type: Review

References (54)

1. Smith DG, Waksman SA. Tuberculostatic and tuberculocidal properties of streptomycin. J. Bacteriol. 54(2), 253-261 (1947).
2. Fleming A. The development and use of penicillin. Chic. Med. Sch. Q. 7(2), 20-28 (1946).
3. Kasik JE, Weber M, Winberg E, Barclay WR. The synergistic effect of dicloxacillin and penicillin G on murine tuberculosis. Am. Rev. Respir. Dis. 94(2), 260-261 (1966).
4. Solotorovsky M, Bugie EJ, Frost BM. The effect of penicillin on the growth of Mycobacterium tuberculosis in Dubos' medium. J. Bacteriol. 55(4), 555-559 (1948).
5. Kasik JE. The nature of mycobacterial penicillinase. Am. Rev. Respir. Dis. 91, 117-119 (1965).
6. Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 99(4), 1025-1026 (1991).
7. Yew WW, Wong CF, Lee J, Wong PC, Chau CH. Do ß-lactamYß- lactamase inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary tuberculosis? Tuber. Lung Dis. 76(1), 90-92 (1995). Compare with Chambers et al. published in the same year. 8 Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu. Rev. Biochem. 64, 29-63 (1995).
8. Ortalo-Magné A, Dupont MA, Lemassu A, Andersen AB, Gounon P, Daffé M. Molecular composition of the outermost capsular material of the tubercle bacillus. Microbiology (Reading, Engl.) 141(Pt. 7), 1609-1620 (1995).
9. Tipper DJ, Strominger JL. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-d-alanyld-alanine. Proc. Natl Acad. Sci. USA 54(4), 1133-1141 (1965).
10. Chambers HF, Moreau D, Yajko D et al. Can penicillins and other ß-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39(12), 2620-2624 (1995).
11. Wietzerbin J, Das BC, Petit JF, Lederer E, Leyh-Bouille M, Ghuysen JM. Occurrence of d-alanyl-(d)-meso-diaminopimelic acid and meso-diaminopimelyl- mesodiaminopimelic acid interpeptide linkages in the peptidoglycan of mycobacteria. Biochemistry 13(17), 3471-3476 (1974).
12. Goffin C, Ghuysen JM. Biochemistry and comparative genomics of SxxK superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin-susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent. Microbiol. Mol. Biol. Rev. 66(4), 702-738 (2002).
13. Mainardi JL, Hugonnet JE, Rusconi F et al. Unexpected inhibition of peptidoglycan ld-transpeptidase from Enterococcus faecium by the ß-lactam imipenem. J. Biol. Chem. 282(42), 30414-30422 (2007).
14. Sifaoui F, Arthur M, Rice L, Gutmann L. Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in Enterococcus faecium. Antimicrob. Agents Chemother. 45(9), 2594-2597 (2001).
15. Lavollay M, Arthur M, Fourgeaud M et al. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by l,dtranspeptidation. J. Bacteriol. 190(12), 4360-4366 (2008).
16. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43(3), 717-731 (2002).
17. Gupta R, Lavollay M, Mainardi JL, Arthur M, Bishai WR, Lamichhane G. The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 16(4), 466-469 (2010).
18. Nguyen L, Thompson CJ. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol. 14(7), 304-312 (2006).
19. Bardou F, Raynaud C, Ramos C, Lanéelle MA, Lanéelle G. Mechanism of isoniazid uptake in Mycobacterium tuberculosis. Microbiology (Reading, Engl.) 144(Pt. 9), 2539-2544 (1998).
20. Colangeli R, Helb D, Sridharan S et al. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol. Microbiol. 55(6), 1829-1840 (2005).
21. Stephan J, Mailaender C, Etienne G, Daffé M, Niederweis M. Multidrug resistance of a porin deletion mutant of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48(11), 4163-4170 (2004).
22. Hackbarth CJ, Unsal I, Chambers HF. Cloning and sequence analysis of a class A ß-lactamase from Mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 41(5), 1182-1185 (1997).
23. Voladri RK, Lakey DL, Hennigan SH, Menzies BE, Edwards KM, Kernodle DS. Recombinant expression and characterization of the major ß-lactamase of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42(6), 1375-1381 (1998).
24. Flores AR, Parsons LM, Pavelka MS Jr. Genetic analysis of the ß-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to ß-lactam antibiotics. Microbiology (Reading, Engl.) 151(Pt 2), 521-532 (2005).
25. Coira A, Salvadó M, Reig R, Chaves J, Segura C. ß-Lactamase activity in mycobacteria other than M. tuberculosis. J. Chemother. 7(2), 106-108 (1995).
26. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS. Meropenemclavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323(5918), 1215-1218 (2009).
27. Dinçer I, Ergin A, Kocagöz T. The vitro efficacy of ß-lactam and ß-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 23(4), 408-411 (2004).
28. Drawz SM, Bonomo RA. Three decades of ß-lactamase inhibitors. Clin. Microbiol. Rev. 23(1), 160-201 (2010).
29. Ambler RP. The structure of ß-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289(1036), 321-331 (1980).
30. Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 208(5007), 239-241 (1965).
31. Matthew M, Hedges RW, Smith JT. Types of ß-lactamase determined by plasmids in gram-negative bacteria. J. Bacteriol. 138(3), 657-662 (1979).
32. Paterson DL, Bonomo RA. Extendedspectrum ß-lactamases: a clinical update. Clin. Microbiol. Rev. 18(4), 657-686 (2005).
33. Queenan AM, Bush K. Carbapenemases: the versatile ß-lactamases. Clin. Microbiol. Rev. 20(3), 440-458 (2007).
34. Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-ß-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53(12), 5046-5054 (2009).
35. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10(9), 597-602 (2010).
36. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-ß-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18(2), 306-325 (2005).
37. Jacoby GA. AmpC ß-lactamases. Clin. Microbiol. Rev. 22(1), 161-182 (2009).
38. Ledent P, Raquet X, Joris B, Van Beeumen J, Frère JM. A comparative study of class-D ß-lactamases. Biochem. J. 292(Pt. 2), 555-562 (1993).
39. Wang F, Cassidy C, Sacchettini JC. Crystal structure and activity studies of the Mycobacterium tuberculosis ß-lactamase reveal its critical role in resistance to ß-lactam antibiotics. Antimicrob. Agents Chemother. 50(8), 2762-2771 (2006).
40. Helfand MS, Bethel CR, Hujer AM, Hujer KM, Anderson VE, Bonomo RA. Understanding resistance to ß-lactams and ß-lactamase inhibitors in the SHV ß-lactamase: lessons from the mutagenesis of SER-130. J. Biol. Chem. 278(52), 52724-52729 (2003).
41. Thomas VL, Golemi-Kotra D, Kim C, Vakulenko SB, Mobashery S, Shoichet BK. Structural consequences of the inhibitorresistant Ser130Gly substitution in TEM ß-lactamase. Biochemistry 44(26), 9330-9338 (2005).
42. Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis ß-lactamase by clavulanate. Biochemistry 46(43), 11998-12004 (2007).
43. Tremblay LW, Hugonnet JE, Blanchard JS. Structure of the covalent adduct formed between Mycobacterium tuberculosis ß-lactamase and clavulanate. Biochemistry 47(19), 5312-5316 (2008).
44. Maveyraud L, Mourey L, Kotra L et al. Structural basis for clinical longevity of carbapenem antibiotics in the face of challenge by the common class A ß-lactamases from the antibiotic-resistant bacteria. J. Am. Chem. Soc. 120(38), 9748-9752 (1998).
45. Zafaralla G, Mobashery, S. Facilitation of the ?2 to ?1 pyrroline tautomerization of carbapenem antibiotics by the highly conserved arginine 244 of class A ß-lactamases during the course of turnover. J. Am. Chem. Soc. 114, 1505-1506 (1992).
46. Nukaga M, Bethel CR, Thomson JM et al. Inhibition of class A ß-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J. Am. Chem. Soc. 130(38), 12656-12662 (2008).
47. Tremblay LW, Fan F, Blanchard JS. Biochemical and structural characterization of Mycobacterium tuberculosis ß-lactamase with the carbapenems ertapenem and doripenem. Biochemistry 49(17), 3766-3773 (2010).
48. Triboulet S, Arthur M, Mainardi JL et al. Inactivation kinetics of a new target of ß-lactam antibiotics. J. Biol. Chem. 286(26), 22777-22784 (2011).
49. Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26(4), 874-877 (1998).
50. Donald PR, Sirgel FA, Venter A et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand. J. Infect. Dis. 33(6), 466-469 (2001).
51. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 49(7), 2816-2821 (2005).
52. Dauby N, Muylle I, Mouchet F, Sergysels R, Payen MC. Meropenem/ clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr. Infect. Dis. J. 30(9), 812-813 (2011).
53. Veziris N, Truffot C, Mainardi JL, Jarlier V. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob. Agents Chemother. 55(6), 2597-2600 (2011).
54. Segura C, Salvadó M, Collado I, Chaves J, Coira A. Contribution of ß-lactamases to ß-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 42(6), 1524-1526 (1998).